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Summary
Actinic keratosis (AK) affects millions of people world-
wide, and its prevalence continues to increase. AK lesions
are caused by chronic ultraviolet radiation exposure, and
the presence of two or more AK lesions along with pho-
todamage should raise the consideration of a diagnosis of
field cancerization. Effective treatment of individual le-
sions as well as field cancerization is essential for good
long-term outcomes.
The Swiss Registry of Actinic Keratosis Treatment
(REAKT) Working Group has developed clinical practice
guidelines for the treatment of field cancerization in pa-
tients who present with AK. These guidelines are intended
to serve as a resource for physicians as to the most appro-
priate treatment and management of AK and field cancer-
ization based on current evidence and the combined prac-
tical experience of the authors. Treatment of AK and field
cancerization should be driven by consideration of relev-
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Introduction
Actinic keratoses (AKs) are caused by chronic ultraviolet
(UV) radiation exposure. Two or more AKs on photodam-
aged skin signal field cancerization and an increased risk
for invasive non-melanoma skin cancer (NMSC). Switzer-
land has one of the highest rates of NMSC in Europe.
Treatment of AK is thus an important Swiss public health
issue.
The Swiss Registry of Actinic Keratosis Treatment
(REAKT) Working Group (referred to herein as the
REAKT Working Group) was formed under a mandate
of the Swiss Society for Dermatology and Venereology
(SGDV). The REAKT Working Group determined that
guidelines for the treatment of field cancerization in AK
were needed, as existing guidelines have focused primarily
on the treatment of discrete AK lesions. The REAKT group
developed the clinical practice guidelines herein based on
available data and a consensus of best practices in field
treatment. Current and emerging therapies were considered
in order to support optimum patient care now and as new
options become available.
These guidelines present the consensus of the REAKT
Working Group regarding the desired approach to field
cancerization based on disease presentation and patient and
treatment considerations. These recommendations are not
intended to be followed rigidly, but to serve as a guide
for clinical care. It must be noted that although field can-
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cerization is associated with other forms of NMSC-includ-
ing Bowen’s disease, squamous cell carcinoma (SCC), and
basal cell carcinoma (BCC)-these forms are outside the
scope of these guidelines for detailed discussion of treat-
ment modalities.
About these guidelines
Methodology
The Swiss Clinical Practice Guidelines on Field Canceriza-
tion of the Skin have been developed by an expert panel of
Swiss dermatology-oncology physicians (members of the
REAKT Working Group) to guide other dermatologists in
their approach to care for patients who have clinically ap-
parent photodamage, AK lesions, or field cancerization, or
who are at risk for NMSC. Prof. Dr. Gunther Hofbauer was
asked to initiate the creation of the guidelines by drafting
an initial manuscript and treatment algorithm based on his
knowledge of the general treatment consensus and prac-
tice approaches of the other members of the REAKT Work-
ing Group. All members of the REAKT Working Group
reviewed the draft manuscript and treatment algorithm in
the month of June 2013 and convened in Bern, Switzerland
on 1 July 2013 to discuss and revise the guidelines. The
guidelines and treatment algorithm were revised following
the meeting and the group convened again in Bern,
Switzerland in December 2013 to review and discuss the
revised guidelines. Further revisions were made and the fi-
nal version was approved on 9 March 2014.
Evidence basis
The REAKT Working Group considered all currently avail-
able treatments for AK in the development of the
guidelines. The treatments specifically recommended with-
in the guidelines are those that the REAKT Working Group
members agreed have the most clinical experience, the best
evidence to consider for treatment of AK, or are of high in-
terest currently based on factors such as clinical trial data
or mechanism of action. The recommendations for use of
each treatment are evidence-based where possible, and are
based on the quality of evidence as well as disease, patient,
and treatment considerations.
The 2011 Oxford Centre for Evidence Based Medicine
(OCEBM) Levels of Evidence (LOE) were used to charac-
terise the strength of the efficacy evidence for field cancer-
ization available for each treatment [1]. The OCEBM LOE
are intended to help guide clinical decision-making. They
do not provide definitive judgment of the quality of evid-
ence, nor do they provide a recommendation for treatment.
Clinical judgment must be applied when considering the
LOE for an individual treatment in order to determine its
appropriate use.
Disclaimers and cautions
These guidelines for treatment of field cancerization have
been prepared for dermatologists who treat patients who
have or are at risk for NMSC. The general principles that
underlie the guidelines are applicable to dermatologists
in many different regulatory environments. However, the
treatment algorithm and guidance is provided to address
the specific needs of the Swiss dermatology oncologist and
it is not our intent to provide specific recommendations that
counter established practices in other countries.
In addition, these guidelines have been developed based on
the consensus of the REAKT Working Group members as
to the preferred treatment approaches based on evidence
available as of the manuscript submission date. Caution
should be exercised in interpreting our recommendations in
the context of newer data, as advances in knowledge and
expansion in treatment options may require reconsideration
of these recommendations.
Finally, the intention behind the development of the Swiss
Clinical Practice Guidelines on Field Cancerization of the
Skin was to aid dermatology physicians in the decision-
making process by highlighting significant considerations
that should guide treatment and providing expert perspect-
ive on the evidence to date on the range of treatments
available for AK and associated field cancerization. The
guidelines and algorithm are not intended to replace a phys-
ician’s best judgement on the most appropriate path for
each individual patient. The REAKT Working Group mem-
bers hope that these guidelines will support and strengthen
reader decisions on appropriate patient care.
Actinic keratosis and field
cancerization background
AKs are UV light-induced discrete intraepidermal lesions
typically presenting as rough, scaly, keratotic macules, pap-
ules or plaques. AK is an indicator of cumulative UV ex-
posure, and lesions typically appear on skin that has been
subject to chronic exposure--the so-called “sun terraces” of
the skin, including the face, chest, ear lobes, balding scalp,
and backs of arms and hands. Patients may present with a
single lesion, but the typical clinical presentation is mul-
tiple lesions across an area of sun-damaged skin. A seminal
Australian study of more than 1,000 people over the age of
40 found an average of 7.7 lesions per person with AK [2].
AKs are now understood as part of a disease continuum ini-
tiated by UV radiation. Photodamage represents the earli-
est stage in the continuum, with the formation of AKs, and
ultimately SCC, demonstrating increasing progression. Be-
fore invasive SCC develops, intraepithelial changes occur
in the clinical forms of AK and Bowen's disease. While
only the latter is traditionally called carcinoma in-situ due
to its total loss of regular architecture of the epidermis, we
believe that AK is part of the continuum of SCC devel-
opment based on histological and molecular changes com-
mon to AK, Bowen’s disease, and invasive SCC [3]. While
we realise that not all of the community shares this strict
parlance based solely on biological parameters, for clarity's
sake we will address AK and Bowen’s disease in this paper
as SCC in situ.
Histologically, AK is characterised by atypia or dysplasia
of the keratinocytes in the basal layer of the epidermis
and with progression in epidermal layers above. Disordered
maturation of the superficial layers results in alternating
areas of parakeratosis and hyperkeratosis [4]. Several his-
tological subtypes have been described, including lichen-
oid, hypertrophic, bowenoid, pagetoid, and pigmented [5,
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6]. Histologically, AK and SCC are indistinguishable in the
epidermis [3].
A significant advance leading to more effective treatment
of AK is acceptance of field cancerization as an underlying
condition driving disease pathology and progression. UV
exposure is believed to generate field cancerization via
several actions: multiple individual foci of cellular trans-
formation, broad immunosuppression and reduced immun-
osurveillance, and additional mutations leading to the de-
velopment of invasive tumours [7]. It is widely accepted
that visible AK lesions (whether few or many) are a mani-
festation of pervasive damage and that the surrounding area
(“field”) of sun-damaged skin contains subclinical lesions
and cellular changes. Bowen’s disease, SCC, and BCC are
also visible indicators of this damage. The presence of any
of these NMSC lesions (to include AK) represents eviden-
ce of field cancerization.
The current focus of AK treatment is to target field can-
cerization, rather than limiting treatment to clinically ap-
parent individual lesions. This approach may help delay
or prevent the development of new lesions [8, 9], and is
suggestive of a reduced future risk for SCC, although as
yet there is little evidence demonstrating these beneficial
outcomes. It may be helpful to envision this treatment ap-
proach as analogous to the use of hypertensive medication
to prevent endpoint events such as stroke and myocardial
infarction. Stroke and myocardial infarction are significant
events that require immediate, focused medical attention,
but treatment limited to the individual event does not ad-
equately promote optimum long-term outcomes. The view
of AK must similarly be broadened to understand that treat-
ment of field cancerization should address underlying risk
factors and may promote better long-term health outcomes
and improved quality of life.
Epidemiology and risk factors
AKs occur more frequently in regions with higher UV ex-
posure and in fair-skinned populations. A 2006 report from
the World Health Organization noted a clear relationship
between latitude and AK prevalence as well as the likeli-
hood of multiple AKs at lower latitudes [10]. Prevalence
rates of 40%–60% in adults in Australia and 11%–25% in
various northern hemisphere populations have been repor-
ted [11]. Prevalence rates are greater in males than in fe-
males and increase with age [11].
The most notable risk factor for development of AK is
accumulated chronic UV radiation exposure, whether
through occupational or recreational means, and the person
with AK typically presents with characteristic signs of pho-
todamage, including freckles and solar lentigines. Recently
published results from a multicentre study across eight
European countries provides additional information about a
number of risk factors [12]. Differences in risk were noted
among hair and eye coloration: red hair conferred a sev-
en times higher risk than black hair; brown eyes about a
40% reduced risk when compared to blue. The presence of
even a few freckles on the face was found to confer great-
er risk. Outdoor occupation, history of sunburns as a child,
and residency in a tropical country were all associated with
increased risk, whereas higher education levels were as-
sociated with a significantly reduced risk. This study also
noted potentially significant increased risks in patients tak-
ing photosensitising thiazide diuretics and cardiac drugs,
and a possible protective effect from nonsteroidal anti-in-
flammatory drugs (NSAIDs).
Patients who are immunocompromised are at significant
increased risk for development of NMSC, as are patients
with genetic disorders such as xeroderma pigmentosum.
AK progression to SCC
Although not all AKs will progress to SCC ‒ and, indeed,
some AKs will regress ‒ there is a clear relationship
between AK and SCC. A review of the evidence supporting
this relationship found that approximately 90% of SCCs
may have contiguous AKs, consistent with the concept that
AKs are pre-invasive forms of SCC [4]. One study found
that up to 60% of SCCs arise directly from an AK [13].
Another study found that 136 of 165 cutaneous SCCs ex-
amined were closely associated with AKs; of these, 26.7%
of the SCCs were found to have arisen directly from an ex-
isting AK lesion, and another 55.7% were in close proxim-
ity to an AK lesion [14].
The proportion of AK lesions that progress to invasive SCC
is not conclusively known, with published progression es-
timates ranging widely from 0.075% to 16% or even more
[2, 13, 15, 16] A recent systematic review concluded that
annual rates of progression of a single AK into SCC range
from 0% to 0.53%, but cautioned that these remain un-
certain estimates [17]. A large majority of lesions remain
Figure 1
Actinic keratosis and field cancerization treatment algorithm
The algorithm is intended to aid in the treatment decision process
for actinic keratosis and field cancerization and is not intended to
replace a physician’s best judgement on the most appropriate
treatment path for each individual patient.
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stable and others will regress. The review found that an-
nual rates of regression for single lesions ranged between
15% and 63%, with recurrence rates of 15%–53% [17]. At
present, it is not possible to determine which AK lesions
will progress to SCC, or regress, or when.
The uncertainty of the timing and likelihood of AK pro-
gression has stimulated much discussion regarding the best
treatment approach to AK, with some advocating watchful
waiting and others a more aggressive approach. It is the
perspective of the REAKT Working Group that we must
consider AK a serious precursor to more invasive disease
and treat promptly. Switzerland has one of the highest skin
cancer rates in Europe, with an incidence of around 15,000
new cases of NMSC each year and steadily rising [18].
Improved treatment approaches to AK as well as compre-
hensive public education efforts are needed to help slow
the rising incidence and improve long-term outcomes for
our population. Rigorous NMSC prevention efforts, both
individually and community-wide, may have financial be-
nefits. A German study of hospitalisation costs associated
with melanoma and NMSC skin cancers found that while
NMSC mortality is low, annual hospitalisation costs related
to NMSC are approximately 100% greater than with
melanoma skin cancer, representing a significant public
health burden that is perhaps not well understood when
viewed solely in the context of death rates [19]. The treat-
ment algorithm presented with these guidelines will present
the REAKT Working Group’s recommendations on appro-
priate treatment path based on patient presentation and risk
factors, balancing health, fiscal, and quality-of-life con-
cerns (fig. 1).
Prevention
As stated, chronic UV radiation exposure is understood to
play an essential role in the development of AK and oth-
er forms of NMSC. Childhood and adolescence are pivotal
periods for prevention efforts, which should focus on redu-
cing overall exposure (minimising the incidence of child-
hood sunburn) and helping to establish life-long self-care
habits. Steadily increasing rates of NMSC highlight the
need for primary prevention measures starting in childhood
to reduce overall population-based risk for AK and NMSC.
Prevention measures focus on limiting UVA (ultraviolet-
A) photodamage through avoidance of unnecessary expos-
ure to UV light (including artificial sources) and the use
of sunscreen when exposure is unavoidable. A study of the
sun protection knowledge and behaviours of 887 children
and adolescents (ages ranging from 8–17 years) in North-
west Switzerland revealed that, despite wide ranging skin
cancer education and prevention campaigns, an opportun-
ity remains to improve child and adolescent knowledge and
behaviour in this regard [20]. The study authors identi-
fied needs for continued education about the potential long-
term effects of excessive sun exposure, proper sunscreen
application, and the effectiveness of clothing and shade as
protective measures. They also noted the need for contin-
ued efforts on changing societal values related to tanned
skin.
In adult patients, including those who have a history of
AKs or other NMSC, randomised clinical trials have
demonstrated that the use of sunscreen reduces the in-
cidence of AKs and SCC. A randomised, controlled trial
spanning 4.5 years demonstrated reduction in SCC (but
not BCC) through the regular use of sunscreen [21]. An
eight year follow-up study evaluated the long-term effects
of sunscreen application during the trial [22]. SCC rates
were significantly reduced by almost 40% during the entire
follow-up period. Most of this effect was attributed to
latency of effect of sunscreen intervention during the trial.
However, the study authors also noted that the intervention
group continued to use sunscreen at a higher rate than the
control group after the initial trial. A 2009 analysis in Aus-
tralia found that regular sunscreen use was a cost-effect-
ive approach to skin cancer prevention, saving almost US
$90,000 in total healthcare costs over a 5 year period for
approximately 800 patients studied [23].
High-risk populations may also benefit from sunscreen use.
Ulrich and colleagues studied the protective effects of reg-
ular sunscreen use on the development of NMSC in organ
transplant recipients (OTR) [24]. At the conclusion of a 24
month study, the intent-to-treat sunscreen group had not-
ably more favourable outcomes, with reduction in lesion
count from baseline and fewer lesions overall than the con-
trol group.
Judicious use of systemic chemoprevention strategies may
also be of benefit in very high-risk patients. Evidence sug-
gests that the use of acitretin may have some benefit [25].
Two small, open-label studies demonstrated some protect-
ive benefits of oral capecitabine in OTR [26, 27]. Studies
are currently underway to evaluate the efficacy of
afamelanotide, a first-in-class photoprotective drug, for use
as a photoprotective agent for OTR patients.
Actinic keratosis and field
cancerization management
Table 1 outlines the REAKT Working Group’s recom-
mendations for screening and management of AK and field
cancerization based on patient and disease factors. Absent
specific risk factors, we recommend encouraging patients
to perform skin self-examination every 3 months, with clin-
ical examination if new lesions are noted. Certain risk
factors require more frequent self and clinical exams, as
noted in the table. In any patient type, suspicious lesions
necessitate timely professional inspection.
Professional screening for AK and field cancerization of-
fers several important benefits. It enables the patient and
physician to establish a baseline (at first screening) or note
changes to the patient’s skin since the last visit, thereby po-
tentially promoting earlier identification of new or chan-
ging lesions. It also offers the opportunity to evaluate for
other skin cancers, such as melanoma. Skin examinations
should be comprehensive, including areas such as the
scalp, palms, oral cavity, and genitalia. For patients at high
risk for invasive skin cancer (e.g., those with history of
melanoma or who have large lesions) it is recommended
that the examination include palpation of the lymph nodes.
Clinician visits also offer the opportunity to introduce or
reinforce prevention and self-care habits, whether through
consultation or the provision of written materials. Patients
are the ultimate drivers of their care; however, they are typ-
Review article Swiss Med Wkly. 2014;144:w14026
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 19
ically noncompliant with screening recommendations, and
continued education is needed to emphasise the import-
ance of regular at-home self-examination as well as clin-
ical examination of new lesions. Patient education on the
importance of screening and the types of changes that need
to be watched versus the changes that require immediate
professional evaluation is key to a successful management
programme. As part of this education, patients should be
trained on how to effectively perform skin self-examina-
tion.
Patients with chronic lymphocytic leukaemia (CLL) as
well as OTR and other patients on long-term immunosup-
pression require special consideration for screening. These
patients should be treated as at high risk for invasive
NMSC. Annual clinical exams by a dermatology specialist
and monthly skin self-examinations are encouraged for
these patients; OTR should be screened by a dermatologist
for NMSC prior to transplantation [28]. The extent and,
particularly, the invasiveness of skin lesions can be clinic-
ally underestimated in OTR and patients with CLL, and le-
sions in these patients should be viewed with a high degree
of clinical suspicion.
Clinical assessment/diagnosis
AK lesions are typically clinically diagnosed. AK has var-
ied presentations, but broadly presents as a scaly, ill-
defined macule, papule, or plaque, commonly flesh-col-
oured, pink or reddish-brown. A classic feature of many
AKs is a rough “sandpaper” feel that is as important to dia-
gnosis as visual inspection. AK lesions may be solitary, but
more commonly present as multiple lesions in a photodam-
aged field. Clinical variants of AK have specific distinct
characteristics that must be noted for differential diagnos-
is. Firm, raised lesions are at greater risk for invasive car-
cinoma and should be biopsied.
Dermoscopy is very effective in helping to diagnose AK.
A prospective study of 178 patients compared diagnostic
results obtained with dermoscopy to histopathological find-
ings [29]. Independent blinded comparison of the results
obtained through both methods resulted in a concordance
of 0.917. The sensitivity of dermoscopy for the diagnosis
of AK was 98.7%, with a specificity of 95.0%. The value
of dermoscopy as a diagnostic tool is reliant on the expert-
ise of the physician, and recognition of the dermatoscopic
characteristics of AK lesions is necessary for accurate dia-
gnosis. A red pseudo-network is a widely cited character-
istic dermatoscopic finding of AK and is significantly as-
sociated with AK [30, 31]. Other features include a pattern
of linear wavy vessels in facial non-pigmented lesions and
multiple gray or brown dots and globules around the fol-
licular ostia in pigmented lesions [30]. Dermoscopy is in-
creasingly used to evaluate the outcomes of NMSC treat-
ment, and should be viewed as a helpful management tool
beyond the initial diagnosis.
Field cancerization should be considered when multiple
lesions of epithelial skin cancer (including in situ SCC
such as AK and Bowen’s disease or invasive tumours such
as SCC and BCC) occur. Moreover, chronic sun damage
defined by the presence of one or more clinical signs such
as skin atrophy, inhomogeneous pigmentation, derma-
tochalasis, Purpura senilis Bateman, or Pseudocicatrices
stellaires should be assessed. Once two or more lesions
of AK, Bowen’s disease, invasive SCC, or BCC with ac-
companying photodamaged skin have been diagnosed in a
single patient, a diagnosis of field cancerization is warran-
ted.
Treatment considerations
Although at this time it is not possible to predict which
AKs will progress to invasive SCC, early diagnosis and
treatment is believed to be key for minimising disease pro-
gression and severity. It is the REAKT Working Group’s
recommendation that each patient with AK receive treat-
ment that addresses both visible lesions as well as the
subclinical damage across the broader field. Although not
yet well documented, we believe that timely and effective
treatment of field cancerization has the potential to im-
prove long-term health prognosis, may reduce the econom-
ic burden associated with treatment of more progressive
disease, and may maximise cosmetic outcomes by reducing
Table 1: Management recommendations for actinic keratosis and field cancerization.
Patient presentation Recommended management Suggested timing Additional information
Clinical skin examination If new lesions occurPhotodamage; no other risk factors
Patient-directed self-examination Every 3 months
Clinical skin examination Every 12 monthsFewer than five lesions; no other risk
factors Patient-directed self-examination Every 3 months
Clinical skin examination Every 3, 6, and 12 months following
treatment
At least every 6 months thereafter
Recurrent lesions and recalcitrant lesions
Patient-directed self-examination Every 3 months
Recalcitrant lesion requires biopsy
by dermatologist
Clinical skin examination Every 3, 6, and 12 months following
treatment
At least every 12 months thereafter
History of skin cancer
Patient-directed self-examination Every 3 months
Lymph node exam by dermatology
specialist in high-risk patients
Clinical skin examination by dermatology
specialist
For CLL:
Every 12 months
For OTR:
One screening exam pretransplantation
Clinical exam at least every 12 months
following transplantation
CLL/OTR
Patient-directed self-examination Every month
Invasiveness of skin lesions can be
clinically underestimated in CLL/OTR.
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the need for more invasive treatments associated with more
invasive skin cancers [8, 9].
Based on the patient’s presentation and risk characteristics,
the treatment strategy may differ (table 2). Treatment suc-
cess is dependent on selecting an appropriate therapy with-
in the context of a range of influencing disease, treatment,
and patient-specific factors. Treatment decisions must ulti-
mately balance efficacy, tolerability, and usage considera-
tions. Regardless of the treatment path selected, the goals
of AK treatment remain fundamentally the same: to clinic-
ally and histologically cure the lesions, minimise pain and
adverse events, and reduce recurrence. When working to-
ward these goals, clinical trial and other study data must
be considered within the context of “real world” practice.
Measures of efficacy in clinical trials include complete
clearance, reduction in lesion count, and sustained clear-
ance rates [32]. Most studies rely exclusively on a clinical
count of AKs; counts conducted even by experienced der-
matologists show marked heterogeneity [33]. Perhaps the
most significant measure of efficacy is sustained clearance
of the total treatment field. Sustained field clearance en-
ables longer disease-free windows for patients, enhancing
quality of life and possibly reducing overall treatment bur-
den.
Treatment decisions must also be weighed against tolerab-
ility data and the burden presented by the treatment regi-
men in the context of the patient’s disease considerations.
For example, in a patient with no known risk factors and a
single clinical lesion the treatment path may appropriately
be quite different from that of the patient with many visible
lesions in a damaged field and a history of prior NMSC.
Lesion location is an important factor, as lesions located in
difficult-to-treat areas (e.g., the back) may prove too bur-
densome for patient-directed home-based treatment. The
treatment algorithm we provide herein as a guide to treat-
ment decisions provides different general paths dependent
on the patient’s disease severity and unique risk profile. Ul-
timately, your professional judgement of what is best for
your patient should drive your final decision.
Specific considerations related to the patient’s lifestyle,
competence, and attitude toward treatment should signific-
antly influence the treatment decision, as they are all im-
portant contributors to the patient’s adherence behaviours.
Patient nonadherence to therapy is a pervasive problem in
healthcare and is a complex issue influenced by many so-
cial, economic, disease, patient, and treatment factors [34].
Because treatment adherence is the foundation of good out-
comes, it is essential to anticipate common factors asso-
ciated with poor adherence and effectively work to over-
come patient barriers. Some barriers to treatment adherence
are somewhat easier to overcome by choosing therapeut-
ic regimens that are less complex or those that better re-
flect patient preferences for administration or vehicle, as
appropriate. Other barriers are more difficult, such as sus-
tained commitment required for certain treatment plans.
A treatment path must be selected that considers the pa-
tient’s ability and willingness to adhere to therapy, and in
some circumstances these factors will outweigh the other
considerations in favour of a particular therapy. For ex-
ample, certain treatments are physician directed by design
and may be appropriate choices for patients that you be-
lieve may be less adherent to therapy because of such is-
sues as health, lesion location, or willingness to adhere
to long-term therapeutic regimens. Topical therapies are
typically patient driven and thus may be more convenient
for patients who are able to manage their own treatment.
However, many topical therapies require longer-term treat-
ment administration of several weeks or more, which raises
the possibility of poor adherence attributable to treatment
fatigue and dissatisfaction due to side effects.
Treatment options
Treatment approaches to AK can be broadly divided into
lesion-directed or field-directed. Lesion-directed therapies
work by physically destroying individual clinically appar-
ent lesions and are best reserved for use in patients who
have only a few isolated lesions and no elevated risk for
development of invasive NMSC. Field-directed therapies
target both clinically visible lesions as well as preclinical
lesions and other changes in keratinocytes in the skin sur-
rounding the visible lesion. Because AK is a visible marker
of more extensive damage caused by chronic UV radiation
exposure, the REAKT Working Group recommends field-
directed therapy as the optimal treatment approach for most
patients.
As discussed in more detail below, each treatment option
has a unique profile. We do encourage the use of treatments
that have shown greater efficacy in treating field canceriz-
ation; however, it is not the intention of the REAKT Work-
ing Group to preferentially promote the use of one modality
or product over another, except within the context of spe-
Table 2: Factors that influence treatment decisions for actinic keratosis and field cancerization.
Disease-specific factors
Progression/development of disease
Number of lesions
Localisation and severity of disease
Location of lesions
Recurrence
Patient-specific factors
Age
Mental condition
Ability and willingness to adhere to therapy
History of skin cancer
Risk factors, especially immunosuppression
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cific patient or disease factors. It should be noted that we
considered the body of evidence available for each treat-
ment when assessing the treatment’s efficacy and when
making recommendations for each treatment’s best use.
Clinical characteristics of AKs vary from study to study
and the reader should be aware that efficacy rates are not
comparable in a head-to-head manner because of differ-
ences in disease presentation, patient characteristics, and
study design, among other factors. Despite these inherent
limitations, the body of evidence does allow us to conclude
that there are a number of safe and effective treatment
approaches, and efficacy rates among various treatments
largely overlap [36]. Each physician should select the ap-
Figures 2A, 2B, 2C:
Summary of treatment-related considerations for actinic keratosis
and field cancerization
Treatments have been assessed according to the subjective
opinions of the authors based on their collective practical
experiences and not necessarily supported by objective data.
Treatments are listed in alphabetical order. It is not the intention of
the REAKT Working Group to preferentially promote the use of one
modality or product over another.
proach that works best for each patient’s needs. Fig. 1
presents a visual guide designed to assist physicians with
the important decision points inherent to determining the
best treatment approach for each individual patient.
Sunscreen
Several studies have demonstrated benefit with regular
sunscreen use for prevention of new AK lesions and mit-
igation of field cancerization progression to SCC and other
invasive skin cancers [21, 24, 37, 38]. One randomised,
placebo-controlled study (n = 588) in Australia also ex-
amined AK lesion remission rates from daily sunscreen use
[38]. In this study, the group using sunblock (broad spec-
trum, SPF 17) had more lesion remissions than in the con-
trol group (OR = 1.53; 95% CI, 1.29–1.80). The authors
noted a clear dose-response relationship that applied to
both the formation of new lesions and remission of existing
lesions.
It is clear that sunscreen use offers some benefit to patients
with field cancerization, probably by removing the tumour
promotion via UV light. Because of this benefit and low
barriers to sunscreen’s use, we recommend that all patients
presenting with field cancerization be encouraged to use
sunscreen frequently (daily is recommended). Education is
recommended to ensure that patients use an appropriate
dose; under-dosing is a common mistake.
Curettage
Curettage is not a first-line therapy for treatment of AKs;
however, some clinicians still advocate its use, as it is a
quick and effective method for clearing visible, discrete
lesions. The treatment requires local anaesthesia and is
best reserved for treating a small number of AKs and/or
thick, hyperkeratotic lesions. Curettage is commonly fol-
lowed by electrodessication to destroy any remaining ab-
normal tissue and to reduce bleeding. Any potential bene-
fits of curettage must be balanced against common adverse
outcomes, including infection, scarring, and pigmentary
changes. Curettage has no benefit in treating subclinical le-
sions or the broader damaged field.
Cryotherapy
Cryotherapy is the most widely used nonsurgical technique
for treatment of a broad range of skin cancers and remains
the most common treatment for AKs [39]. It is procedurally
simple, widely available in both specialist and generalist
offices, and is a quick and effective approach to clinically
apparent lesions. Despite its popularity as a treatment, few
studies have attempted to determine the true efficacy of
cryotherapy in practice, and there is no standardised ap-
proach to frequency, duration, intensity, or temperature of
cryotherapy. This leads to a variety of physician-specific
approaches with resulting differences in outcomes.
A prospective, multicentre study of 90 patients in Australia
recruited expert physicians and allowed them to treat each
patient using the freeze time they felt was appropriate and
adequate based on their clinical experience [40]. Results
from this study revealed a broad range of freeze times
(from 2 s to 1 min 30 s) and complete response rates (on
the face and scalp) from 39% for treatment durations short-
er than 5 seconds to 83% for treatments in excess of 20
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seconds. The study authors noted that the cure rates ob-
tained by these expert physicians were as a whole much
lower than previously reported cure rates with cryotherapy.
In general, higher efficacy rates were linked to longer
freeze times; longer freeze times, in turn, were associated
with higher incidence of undesirable adverse effects. Cos-
metic response was rated “good” or “excellent” in 94% of
the patients who had a 100% response rate at 3 months fol-
lowing treatment. Hypopigmentation was noted in 29% of
the complete response lesions.
In a study of the comparative safety and efficacy of methyl
aminolevulinate (MAL)-photodynamic therapy (PDT)
versus cryotherapy as treatment of AKs on the extremities
of 121 patients, the complete response rate for cryotherapy
at 24 weeks was 88% [41]. The cosmetic outcome was as-
sessed as “excellent” in 56% of patients who received cryo-
therapy. A randomised comparative study of imiquimod
5%, 5–fluorouracil (5–FU), and cryotherapy for treatment
of AKs in 75 patients documented initial and 12 month
clearance rates for each therapy [42]. Cryotherapy was as-
sociated with a 68% initial clearance rate, a 32% histolo-
gical clearance rate, and 12 month sustained clearance rate
for initially cleared lesions of 28%. This study also meas-
ured sustained clearance across the total treatment field; the
sustained field clearance rate for cryotherapy was 4%.
A recent meta-analysis of complete clearance rates associ-
ated with eight common interventions for AK (including
common topical treatments and PDT) found that the ef-
ficacy outcomes from cryotherapy were superior only to
diclofenac and placebo [43]. The authors did note that the
analysis may have tended to favour field-directed treat-
ments over those that were lesion-directed.
Pain, redness, oedema and blistering are common side ef-
fects of treatment with cryotherapy. In addition, significant
local adverse events, such as hyper- or hypopigmentation,
scarring, and hair loss have been observed [40, 44].
Cryopeeling (diffuse cryotherapy) has been suggested as a
possible approach for treating individual AKs as well as the
broader damaged field [45]. Evidence for this treatment is
limited, and no standardisation in approach or methods ex-
ists. More effective and well-tested options are available.
5–Fluorouracil
Topical 5–FU has a long history in dermatology and has
been extensively used as treatment for AK. The drug inter-
feres with deoxyribonucleic (DNA) and ribonucleic (RNA)
synthesis in rapidly dividing cells, preventing cell prolifer-
ation and resulting in cell death. Clinical study of 5–FU has
reported field clearance rates of 42% to 96%, with recur-
rence rates up to 55% [42, 46, 47].
5–FU is associated with an almost 100% incidence of local
skin reactions. Currently, a 5% formulation of fluorouracil
is available in Switzerland for treatment of senile and ac-
tinic keratosis, requiring application once or twice daily for
3–4 weeks, or longer in some cases. A 0.5% fluorouracil
formulation, not yet available in Switzerland, has demon-
strated similar efficacy rates as the 5% formulation, but
appears to cause less severe adverse events and is associ-
ated with improved patient satisfaction [47–49]. A recent
meta-analysis of complete clearance rates ranked both the
5% and 0.5% formulations of 5–FU as superior to the oth-
er interventions evaluated, including common topical treat-
ments, PDT and cryotherapy [43]. These results should be
interpreted with caution as the definition of the efficacy
outcome “complete clearance” varied between the studies
included in the analysis.
A combination product of 5–FU 0.5% plus salicylic acid
(SA) 10% solution is approved in Switzerland for once-
daily application, with clinical trial data available for ex-
periences over 12 weeks of therapy. A randomised mul-
ticentre study compared the combination product to the
study drug vehicle and diclofenac 3% [50]. Patients treated
with the combination 5–FU + SA demonstrated signific-
antly greater histological clearance (72%) and complete
clearance (55.4%) rates at 20 weeks than either the vehicle
or diclofenac. Application-site reactions were more com-
mon with the 5–FU + SA product, but were mostly mild to
moderate.
Diclofenac
Diclofenac sodium 3% gel in a hyaluronic acid vehicle is
approved in Switzerland for treatment of AK with a twice-
daily administration for 60–90 days. Diclofenac is a nons-
teroidal anti-inflammatory cyclooxygenase-2 (COX-2) in-
hibitor. Activation of COX-2 has been implicated in UV-
induced skin cancers; inhibition of the COX-2 pathway has
been shown to significantly reduce UV-induced tumouri-
genesis [51]. Diclofenac sodium 3% gel in hyaluronic acid
also induces apoptosis, which is believed to play an import-
ant role in its effectiveness as an AK treatment [52].
Phase 3 studies of topical treatment with diclofenac
demonstrated complete clearance rates of 33% following
60 days of treatment[53] and 50% following 90 days of
treatment (clearance was assessed 30 days post-treatment
in both studies) [54]. A 2005 meta-analysis of three ran-
domised trials reported an overall complete clearance rate
of 40% (364 patients) [55]. A phase 4 open-label study of
diclofenac in patients with five or more AK lesions demon-
strated similar results, with 41% complete clearance at day
90 of treatment and 58% at the 30–day follow-up visit
[56]. A 12 month extension from this study demonstrated
79% complete clearance of target lesions and 30% for cu-
mulative lesions approximately 1 year post-treatment [57].
Diclofenac is typically associated with mild-to-moderate
application-site reactions.
The results of one case series [58] and a randomised con-
trolled trial [59] suggest that diclofenac sodium 3% gel is
effective and well tolerated as a treatment of AKs in OTR.
The complete clearance rate in the randomised controlled
trial was 41% and overall lesion counts decreased; import-
antly in this high-risk patient group, there were no cases of
invasive SCC or aggressive AK in the 24 month follow-up
period [59].
Imiquimod
Imiquimod is an immune-response modifier that is well
studied for treatment of AK. It is approved in Switzerland
for treatment of clinically typical, nonhyperkeratotic, non-
hypertrophic AKs on the face or scalp. The approved
course of therapy is 3 times per week for 16 weeks. Com-
plete clearance rates from clinical trials of this protocol
range from 48.3% to 57.1% [60, 61]. Long-term follow-up
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data from four phase 3 clinical trials in the US and Canada
revealed that 24.7% of patients who applied imiquimod
three times weekly had a recurrence of AK in the original
treatment area after a median follow-up period of 16
months [62].
Several studies have evaluated the safety and efficacy of
a 4 week treatment protocol. In one vehicle-controlled,
randomised, double-blind study, complete clearance rates
were 26.8% after the first cycle (4 weeks) and 53.7% over-
all following a second cycle in patients with lesions re-
maining after the first cycle [63]. The 12–month sustained
clearance rate was 61%. Another study showed similar res-
ults with an overall complete clearance rate of 55% [64].
Topical imiquimod causes local skin reactions (LSRs), in-
cluding severe erythema, scabbing, and ulceration. In addi-
tion, it has been associated with fairly significant adverse
events, including rare reports that in some patients its use
caused flares of previously controlled auto-immune dis-
eases [65–68]. Despite these potential side effects,
imiquimod is typically well tolerated.
In 2012, a 3.75% imiquimod formulation was approved
in Europe. Clinical trial data demonstrates high clearance
rates and potentially improved patient tolerance with the
lower concentration. Imiquimod was tested in two concen-
trations ‒ 2.5% and 3.75% ‒ applied daily to the full face
or scalp in a 2/2/2 protocol (treatment daily for 2 weeks,
followed by 2 weeks without treatment, and then another 2
weeks with daily treatment) [69]. The complete clearance
rate associated with imiquimod 3.75% 2/2/2 administration
was 35.6% and the partial clearance rate was 59.4% [69].
Two additional placebo-controlled trials evaluated a 3/3/3
regimen (treatment daily for 3 weeks, followed by 3 weeks
without treatment, and then another 3 weeks with daily
treatment) with imiquimod 2.5% and 3.75%, with similar
results [70]. Although most subjects experienced LSRs (up
to 55% of which were considered severe in the 3/3/3 pro-
tocol group), patient adherence rates exceeded 90% in the
trials [69, 70].
Resiquimod (emerging therapy)
Resiquimod is an investigational toll-like receptor 7 and
8 antagonist currently in phase 3 trials in Switzerland for
treatment of AK. Resiquimod’s immunomodulatory effects
are comparable to imiquimod, but it has greater potency
in inducing cytokine expression [71, 72]. A phase 2 dose-
ranging study evaluated the safety and efficacy of four
different concentrations of resiquimod gel (0.01%, 0.03%,
0.06%, and 0.1%), applied once daily three times per week
for four weeks [73]. Studied patients had 4 to 8 AK lesions
on the face or balding scalp. Complete clearance rates after
one course of treatment ranged from 40% (0.01% con-
centration) to 74.2% (0.03% concentration). After an eight
week treatment-free interval, patients with remaining le-
sions received a second course of treatment. Overall com-
plete clearance rates ranged from 77.1% (0.01% concentra-
tion) to 90.3% (0.03% concentration). The most common
adverse events were application-site reactions. In the dose-
ranging study higher concentrations were associated with
a greater incidence of adverse events and more severe ad-
verse events. The lower concentrations (0.01% and 0.03%)
were better tolerated.
Ingenol mebutate
Ingenol mebutate is the most recent entry to the AK treat-
ment armamentarium. It has been available for use in the
US and European Union since 2012, and was approved in
Switzerland in June 2013 for treatment of nonhyperker-
atotic, nonhypertrophic AKs. Ingenol mebutate is a novel
drug that appears to have two distinct and complementary
mechanisms of action: initial rapid lesion necrosis within
hours of application followed by specific neutrophil-medi-
ated, antibody-dependent cellular cytotoxicity within days
[74].
Ingenol mebutate gel is available in two strengths: 150
mcg/g, administered once daily for 3 consecutive days to
the face and/or scalp; 500 mcg/g, administered once daily
for 2 consecutive days to the trunk and/or extremities. A
pooled analysis of 2 phase 3 studies of ingenol mebutate
150 mcg/g for the face/scalp indicated that ingenol me-
butate is significantly more effective than placebo, with a
complete clearance rate of 42.2% versus 3.7% for placebo
(p <0.001) [35]. A pooled analysis of 2 additional phase
3 studies of the 500 mcg/g concentration for the trunk/ex-
tremities revealed similar efficacy, with a complete clear-
ance rate of 34.1% with ingenol mebutate versus 4.7% with
placebo (p <0.001) [35].
LSRs were the most common adverse events in the phase
3 studies [35]. For the 150 mcg/g concentration, LSRs
peaked at day 4 following treatment initiation, rapidly de-
creased by day 8, and then continued to decrease until re-
turning to baseline around day 29. For the 500 mcg/g con-
centration, LSRs peaked between days 3 and 8, and then
followed a similar pattern as with the 150 mcg/g concen-
tration, returning to baseline by about day 29. Fewer than
2% of subjects who received ingenol mebutate experienced
more serious adverse events. More than 98% of patients in
the 4 trials completed the treatment protocol, thus showing
adherence rates similar to those expected with physician-
directed treatments [35].
A total of 171 patients who had achieved complete clear-
ance by day 57 in the ingenol mebutate phase 3 trials com-
pleted a 12 month observational follow-up study [75]. The
patients were seen at 3, 6, 9, and 12 months following their
day-57 visit from their original study. During each visit the
target treatment area was evaluated for presence of AK le-
sions, and total lesions were counted. The primary endpoint
was recurrence of AK in the target treatment area, with an
additional endpoint of the percentage reduction in total AK
lesions from the patient’s original baseline in their original
study. At 12 months, there was a 46% sustained clearance
rate (face and scalp lesions) and an 87% reduction in the
number of AK lesions compared to baseline.
A pharmacokinetic study investigated the potential for sys-
temic absorption of ingenol mebutate and two of its meta-
bolites following topical administration of ingenol me-
butate gel [76]. Approximately 1 gram of ingenol mebutate
gel 0.05% was applied once daily for two consecutive days
to a contiguous 100 cm2 treatment area on the dorsal fore-
arm of 13 patients; 3 patients received vehicle gel in
identical administration. All patients had multiple AK le-
sions in the treated area. Whole blood samples were taken
pre-dose on days 1 and 2, and 7 additional samples were
taken in the 24 hours following the day-2 dose. No system-
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ic exposure of ingenol mebutate or its metabolites was de-
tected in any sample (lower limit of quantification = 0.1 ng/
mL).
Photodynamic therapy
PDT involves the irradiation of AK lesions with light to
cause cell death. Prior to light exposure, a photosensitising
agent is applied; neoplastic cells accumulate more of the
agent than normal cells and are thus subject to greater
thermal and chemical effects. The most frequently used
photosensitising agents are 5–aminolevulinic acid (ALA)
and its methyl ester MAL. MAL-PDT is approved in
Switzerland for treatment of thin or nonhyperkeratotic AKs
on the face or scalp. ALA-PDT is approved for treatment
of mild AKs with a maximum diameter of 1.8 cm on the
face and hairless regions of the scalp. In addition to topical
creams, an ALA patch is also available and demonstrates
similar efficacy as the creams. Treatment protocols for
PDT are not yet standardised; incubation times,
wavelength, and dose differ in both trial and practice. Re-
cent efforts have been made to issue guidelines to help
clarify the most successful approaches for various derma-
tology conditions, including AK and field cancerization
[77–81].
Studies of ALA-PDT and MAL-PDT reveal similar ef-
ficacy. One study of ALA-PDT demonstrated 66% lesion
clearance at 8 weeks (following single treatment) and 85%
at 16 weeks (following retreatment) [82]. Another study of
ALA-PDT demonstrated complete clearance rates of 66%
at week 8 and 73% at week 12 [83]. A study of MAL-
PDT demonstrated complete (lesion) response rates of up
to 89% with retreatment [84]. Pretreatment curettage is of-
ten used in conjunction with PDT and probably enhances
the efficacy rates. PDT is associated with pain (more sig-
nificant with ALA) and hypersensitivity to light. However,
PDT can be used over large areas in a single session and
has been associated with favorable cosmetic results. A re-
cent study demonstrated that MAL-PDT was associated
with reduced keratinocyte atypia on photodamaged skin
(supporting its efficacy in field cancerization) as well as an
increase of new collagen deposition (perhaps explaining its
beneficial cosmetic effect) [85].
In patients with thin AK lesions in large field-cancerized
areas, daylight-mediated PDT may provide an effective and
less painful treatment option [86]. Several small random-
ised clinical studies of daylight-mediated PDT for treat-
ment of mostly thin AK lesions on the face and scalp have
demonstrated 3–month lesion response rates of 75%–79%,
with significantly less pain than reported with conventional
PDT [87–89]. This treatment approach is still in develop-
ment.
Radiotherapy
Radiotherapy (or radiation therapy) is an effective ap-
proach for treatment of AK and field cancerization in pa-
tients who require treatment of a large field with a mul-
tiplicity of lesions [90–92]. In addition, physicians have
reported excellent results using radiotherapy in patients
with lesions that have not been responsive to other treat-
ments [90, 91].
Radiotherapy allows irradiation of large fields (the size of
two outstretched hands) of damaged skin at each session,
and is most commonly used for treatment of the face and
balding scalp. Recommended treatment is six sessions over
three weeks, although some case reports have reported
more sessions [91]. Cosmetic outcomes are typically excel-
lent, and effects of treatment last up to two decades. Ra-
diotherapy treatment for cutaneous neoplasms on the trunk
and limbs has been associated with poorer cosmetic out-
comes [93], but radiotherapy may be used to treat the lower
arms and legs if indicated.
Grenz ray therapy is the preferred modality, as soft X-ray
therapy may induce permanent alopecia. Side effects and
adverse events are typically limited to some mild discom-
fort and reddening of the skin for two weeks following the
treatment. Because there is a small increased risk for de-
velopment of a secondary malignancy due to treatment, ra-
diotherapy is contraindicated for treatment of AK in im-
munosuppressed patients. In addition, radiotherapy is best
reserved for older patients (60 years +) in order to maxim-
ise the typically long-term results of treatment while min-
imising the risk for secondary malignancy, which also has
a typically long-term latency period.
Other therapies
Other treatments for AK are available, but the evidence
behind their use is less robust in comparison to effective
options already presented. We briefly review these other
treatment options and their potential place in the current
armamentarium.
Excision of AK lesions is not a first-line treatment ap-
proach. Shave or punch excision is occasionally used to
treat individual lesions, typically to obtain a specimen for
histologic examination in cases of suspected invasive SCC
[94]. A multicentre, hospital-based case-control study of
dermatology departments in eight European countries ob-
tained information about physician treatment preferences
for skin cancer and found that surgical approaches were the
most common choice for the treatment of most tumours,
with a notable exception in the treatment of AK, where
nonsurgical treatment was recommended in 91.4% of cases
[39]
Skin grafting may have some benefit in high-risk patients.
A retrospective study of eleven kidney transplant patients
who underwent surgical resurfacing of the entire dorsum of
the hand as a treatment for multiple skin cancers demon-
strated no recurrences of skin cancer over a mean follow-
up time of 4.7 years [95]. Cosmetic appearance was accept-
able. The study authors suggested this surgical approach as
a possible prophylactic treatment in patients with severely
actinically damaged skin.
Topical retinoids have been studied for treatment of AK,
but are seldom used by contemporary physicians. Results
from a few studies indicate some limited benefit compared
to placebo; however, recent results from a large randomised
chemoprevention trial in high-risk patients demonstrated
no differences in NMSC development or AK counts
between the tretinoin group and the control group [96].
Skin resurfacing with chemical peels or lasers has shown
some good results. A small, randomised, prospective study
comparing carbon dioxide (CO2) laser resurfacing, 30%
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trichloroacetic acid (TCA) peels, and 5–FU administration
(3 weeks) demonstrated similar efficacy results among the
three treatment groups [97]. The efficacy of chemical peels
is dependent on the agent used, and reported efficacy rates
vary. Similarly, reported efficacy results from laser resur-
facing have varied, as these results are highly dependent
on the skill and technique of the treating physician. More
study of the optimum approach is required to assess where
laser may fit into the AK treatment armamentarium.
Small studies have reported some benefits from dermab-
rasion for treatment of AK. However, these study results
are not compelling. In addition, dermabrasion requires loc-
al anaesthesia and has the potential for significant side ef-
fects, including bleeding and scarring.
Table 3 summarises the available treatments for AK dis-
cussed throughout this section and their efficacy in the
treatment of field cancerization. Fig. 2 presents the
REAKT Working Group’s assessment of each available
treatment within the context of important considerations re-
lated to selecting the optimum treatment for specific pa-
tients.
Combination therapy: concomitant
and sequential approaches
Combination therapy is appropriate for most patients with
AK, and may be especially helpful when treating patients
with many lesions. Although lesion-directed therapy is not
recommended for treatment of field cancerization, judi-
cious use of lesion-directed therapy in combination with
field-directed therapy may prove to the most beneficial
approach in some patients. Combining the use of two or
more modalities or complementary topical agents has sev-
eral theoretical advantages, including the possibility of en-
hanced therapeutic effect and improved utility in recalcit-
rant disease. Although the potential benefits of combina-
tion therapy are significant, there is much to learn about
optimum approaches. The body of evidence in support of
combination therapy is growing, but is currently sparse.
Lack of guidelines or standardised treatment protocols for
use of various modalities or topical agents in combination
also hampers efforts to identify the most useful combin-
ations in practice. The myriad possible combinations also
present added risks for synergistic adverse events, with po-
tential for increased treatment-related pain and LSRs.
PDT in combination
One study of 24 patients demonstrated greater efficacy
resulting from sequential therapy with ALA-PDT +
imiquimod 5% versus ALA-PDT + placebo [98]. A ran-
domised pilot study compared the use of MAL-PDT mono-
therapy, imiquimod 5% monotherapy, and sequential ther-
apy with MAL-PDT + imiquimod 5% in patients with AK
on the face and scalp [99]. Sequential therapy provided a
better response than either therapy alone, with “signific-
antly less intense local reactions” and greater patient satis-
faction than imiquimod 5% monotherapy [99].
Studies have also investigated sequential treatment
strategies using topicals as the initial therapy, followed
by PDT. A small controlled study indicated that pretreat-
ment with tazarotene may enhance the effects of ALA-PDT
across the entire treatment field [100]. A prospective case-
based assessment of sequential application of 5% 5–FU
+ PDT indicated enhanced results over PDT alone [101].
A randomised, placebo-controlled, double-blind pilot study
of 10 patients investigated whether pretreatment with
diclofenac would improve the results obtained from PDT
[102]. Pretreatment with diclofenac was found to signific-
antly reduce lesion count at 12 months, but was associated
with more pain during PDT.
Cryotherapy in combination
A number of studies have investigated the use of cryother-
apy in combination with other therapies. In one random-
ised, double-blind, placebo-controlled study, patients with
AK were treated with cryotherapy followed by applica-
tion of imiquimod 3.75% or placebo cream daily for two
2–week cycles [103]. The results demonstrated that the use
of imiquimod 3.75% post-cryotherapy resulted in subject
complete clearance rates of 60% versus 30% in subjects
who received placebo (p <0.001). The combined therapy
was well tolerated. An open-label study of imiquimod 5%
versus vehicle postcryotherapy found improved efficacy
with the combination in regard to 12 week lesion counts,
although target AK clearance was similar for imiquimod
and vehicle [104].
Similarly, the results of an open-label phase 4 study of 714
enrolled patients found that cryotherapy followed by ap-
plication of diclofenac for 90 days was significantly more
effective at clearing lesions than cryotherapy alone: 64%
achieved complete clearance with sequential therapy
versus 32% with cryotherapy alone [105]. However, more
patients assigned to sequential therapy discontinued treat-
ment because of adverse events. A small case series of pa-
tients who received diclofenac gel for 12 weeks followed
by cryotherapy when needed for recalcitrant lesions
demonstrated a substantial reduction in lesion count and a
mean lesion-free period of 10 months [106]. No treatment
discontinuations due to adverse events were noted.
A randomised controlled trial of the effect of treatment
with 0.5% 5-FU followed by cryotherapy to residual le-
sions at 4 weeks following treatment initiation found that
the combination was significantly more effective in lower-
ing 6 month lesion count when compared to cryotherapy
alone [107].
A phase 3 study is currently in progress comparing the
safety and efficacy of a sequential treatment regimen of
cryotherapy followed by field treatment with ingenol me-
butate gel 0.015% versus cryotherapy followed by vehicle
gel for treatment of AKs on the face and scalp [108]. Com-
plete clearance rates at 11 weeks following sequential treat-
ment with cryotherapy + ingenol mebutate were signific-
antly higher than the rates observed with cryotherapy +
vehicle gel (60.5% vs 49.4%; p = 0.04) [109]. Adverse
events and LSRs were comparable to those observed in oth-
er studies.
Combining topical therapies
Combinations of topical therapies may also be beneficial.
One study of 64 patients tested the combination of two es-
tablished topicals, imiquimod 5% and 5–FU [110]. 48 pa-
tients completed the study and achieved clearance of their
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Table 3: Summary of treatments for actinic keratosis and efficacy in the treatment of field cancerization.
Efficacy in treatment of field cancerizationTreatment LD/FD
Evidence of treatment benefits OCEBM
LOE
Comments
Sunscreen FD Use of sunscreen improves lesion remission and reduces
lesion progression.
2 Use is encouraged adjunctively for all patients.
May be used as sole treatment in some patients.
Should be applied to all sun-exposed areas.
Curettage/
electrodessication
LD Undocumented N/A May be beneficial in hyperkeratotic lesions and in
combination with field therapy.
Localised use preferred over field application.
Cryotherapy LD Some field cancerization benefit reported in a review of
charts from a single practice where patients were treated
with a cryopeeling technique.
4 Widely used lesion-directed treatment.
Physician-directed treatment.
Approach is not standardised, leading to wide range of
outcomes.
Localised use preferred over field application.
5–Fluorouracil FD Complete clearance rates for 5% 5–FU:
• 42%-96%, 4 weeks post treatment
• Sustained clearance rate at 12 months: 33% (one RCT)
Complete clearance rate for 0.5% 5–FU + SA at 8 weeks
following treatment: 55.4%
1 Treatment of large areas possible with occlusion (Unna
boot). This use is physician directed.
Diclofenac FD Complete clearance rate 30 days following treatment:
approximately 40% (meta-analysis of 3 RCTs with
treatment duration either 60 or 90 days)
1 Good cosmesis.
Larger areas can be treated depending on side effects and
patient tolerance.
Imiquimod FD Complete clearance rates after 16 week course: 48.3% to
57.1%
Complete clearance rates after 4 week short course
treatment: 26.8% after one course; 53.7% after two
courses
1 Unmasking of subclinical lesions.
Systemic reactions rarely.
Larger areas can be treated depending on side effects and
patient tolerance.
Resiquimod (currently in
Phase 3)
FD Complete clearance rates 8 weeks following treatment:
• After one course of treatment: 40% to 74.2% (dose
dependent)
After second course of treatment: 77.1% to 90.3% (dose
dependent)
3 Treatment aimed at biological response (inflammation).
Inflammation may be early or late.
Larger areas can be treated depending on side effects and
patient tolerance.
Ingenol mebutate FD Complete clearance rates 57 days following treatment:
• 37%-47% (face)
• 28%-42% (body)
Sustained clearance rates at 12 months following
treatment (patients who had achieved complete clearance
at 57 days):
• 46.1% (face)
• 44% (body)
1 Strong local reaction with short administration time.
Larger areas can be treated depending on side effects and
patient tolerance.
Topical retinoids FD Varied efficacies reported. Recent RCT reported no
observed difference in lesion counts between topical
tretinoin and placebo.
2 Not recommended due to low efficacy.
ALA/MAL + PDT LD and
FD
Lesion clearance rates range from 66% to 89% depending
on photosynthesising agent and treatment regimen. Small
studies indicate benefit for treatment of field cancerization.
3 Physician-directed treatment.
Pain is a consideration, and will limit the size of treatment
field depending on patient preference and previous
experience.
Daylight PDT in development.
Radiotherapy (Grenz ray) FD 13 out of 16 patients had complete clearance 2 weeks
following treatment completion.
4 Physician-directed treatment.
Recommended that its use be limited to patients over 60
years of age.
1 treatment cycle per field per lifetime.
Grenz ray is recommended. Soft X-ray may induce
alopecia.
Larger areas can be treated depending on side effects and
patient tolerance.
Excision LD Undocumented N/A Not a first-line treatment.
Appropriate only for localised use. Typically reserved for
lesions highly suspicious for invasive SCC.
Skin grafting FD 11 out of 11 patients had complete clearance out to 4.7
years.
4 Rarely used; may be helpful in singular cases involving
areas of pronounced field cancerization, such as the back
of the hands.
Chemical peels FD AK lesion reduction of up to 89% reported. 3 May be helpful in select patients.
Larger areas can be treated depending on side effects and
patient tolerance.
Laser FD AK lesion reduction of up to 92% reported. 3 May be helpful in select patients.
Larger areas can be treated depending on side effects and
patient tolerance.
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Dermabrasion FD Some sustained benefit observed in small case series. 4 May be helpful in select patients.
Larger areas can be treated depending on side effects and
patient tolerance.
Note: The level of evidence has been noted based on evidence of each treatment’s efficacy for field cancerization. Treatment comments and recommendations for use are
based on a consideration of available evidence as of the article submission date regarding treatment of field cancerization, in conjunction with the subjective opinions of the
authors based on their collective practical experiences. It is not the intention of the REAKT Working Group to preferentially promote the use of one modality or product over
another except within the context of evidence and experience that supports better efficacy for a patient’s unique presentation.
AKs after 3 treatment cycles; the combination was judged
to be relatively faster and more convenient than either ther-
apy alone. A case-control study of 10 patients confirmed
the potential efficacy of this combination in patients with
treatment-refractory AK [111].
As the therapeutic armamentarium for AK continues to
expand, targeted combination treatment plans will likely
play a larger role in treating AKs and field cancerization.
However, more evidence is needed to determine the com-
binations that provide the best balance of efficacy and
safety in practice.
Management considerations for the
immunocompromised
Patients who are immunocompromised require diligent
monitoring for AKs and other NMSC and aggressive treat-
ment if lesions are noted. Patients with CLL are at signific-
ant elevated risk for development of cutaneous neoplasms;
multiple instances or aggressive forms of skin cancer could
raise suspicion of CLL.
OTR are an important and growing subset of patients at in-
creased risk for the development of NMSC. Advances in
organ transplantation management have increased the sur-
vival time of OTR to 20 years or more following trans-
plantation [112]. OTR are subject to the same risk factors
as the general population, but with the added burden of im-
munosuppressive therapy. It has been estimated that up to
40% of OTR patients develop pre-malignant tumours with-
in the first five years of immunosuppression [112, 113].
OTR also bear increased risk for developing lesions with
unusual presentation and aggressive progression rates.
A Swiss study of 243 renal transplant recipients on immun-
osuppressive therapy confirmed an increased risk for the
development of AKs and NMSC, especially SCC (ratio of
BCC: SCC was 1:7) [114]. Older age, male sex, and fair
skin were factors associated with higher risk for develop-
ing AKs and/or SCC. Increasing duration of immunother-
apy was also a significant factor, although no specific im-
munosuppressive therapy was noted as a distinct risk factor
in this study.
The increased risk of skin cancer may result from de-
creased immunosurveillance as well as drug-specific prop-
erties [115]. A Swiss study of 48 kidney transplant patients
who were receiving either azathioprine (AZA) or my-
cophenolate (MMF) evaluated the skin photosensitivity ef-
fects of changing from AZA to MMF [116]. The study
results revealed that changing from AZA to MMF did re-
duce skin photosensitivity to UVA, but not UVB, in the pa-
tient population tested (primarily skin types II and III). The
results from two small UK studies also indicate increased
UVA photosensitivity in patients taking therapeutic doses
of AZA [117, 118].
The use of calcineurin inhibitors has also been associated
with an increased risk for NMSC. One study noted a 2.8
times greater risk of NMSC when cyclosporine was added
to an immunosuppressive protocol of AZA and predniso-
lone [119]. Another study found that replacing calcineurin
inhibitors with sirolimus reduced the incidence of SCC and
lengthened the time to onset, although adverse events were
significantly greater with sirolimus therapy [115].
Other studies have found no specific connection between
types of immunosuppressive therapy and NMSC risk, and
it is possible that the level of immunosuppression is a
more critical factor than the type [120]. Further comparat-
ive research into the association between immunosuppress-
ive drugs and the incidence of skin cancer will enhance our
understanding of possible risks and may provide valuable
strategies for managing and reducing this risk in the future.
For now, it is important that physicians are aware of these
considerations.
A retrospective analysis of the cost of dermatologic care in
one Swiss clinic found that dermatology care costs for OTR
are high, with the majority of costs due to occurrence of
SCC [121]. Once SCC occurs, the costs of care “increase in
a pronounced and sustained fashion” [121]. Interventions
that limit progression of early lesions to invasive SCC can
result in considerable cost savings.
The immunosuppressed population requires specific tar-
geted surveillance to help ensure early diagnosis and man-
agement of skin cancers. The REAKT Working Group re-
commends that OTR and other patients who are immun-
ocompromised receive yearly comprehensive screening to
ensure early diagnosis of SCC in-situ and timely and ag-
gressive treatment to limit progression. This approach is
likely to improve long-term prognosis as well as reduce
the costs associated with SCC in these populations. Con-
cern has been raised about the safety of immune stimulators
such as imiquimod. However, there is now a body of evid-
ence suggesting that these substances are safe in OTR
[122].
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Figures (large format)
Figure 1
Actinic keratosis and field cancerization treatment algorithm
The algorithm is intended to aid in the treatment decision process for actinic keratosis and field cancerization and is not intended to replace a
physician’s best judgement on the most appropriate treatment path for each individual patient.
Review article Swiss Med Wkly. 2014;144:w14026
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 18 of 19
Figures 2A, 2B, 2C:
Summary of treatment-related considerations for actinic keratosis and field cancerization
Treatments have been assessed according to the subjective opinions of the authors based on their collective practical experiences and not
necessarily supported by objective data. Treatments are listed in alphabetical order. It is not the intention of the REAKT Working Group to
preferentially promote the use of one modality or product over another.
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